Explore the world of dresses


 

 

‘‘Direct Answer:’’ HSV-1 and HSV-2 are two closely related
viruses that cause herpes, but they differ in their typical routes of
transmission and preferred sites of infection. HSV-1 spreads primarily through
oral contact and typically causes oral herpes (cold sores), while HSV-2 spreads
primarily through sexual contact and causes genital herpes . However, this
distinction is not absolute—HSV-1 can also cause genital herpes through oral
sex, and it is increasingly responsible for new genital infections . Neither
virus can be cured, but antiviral medications can reduce symptom duration and
severity .

 

HSV-1 vs. HSV-2: How Herpes Spreads, How to Get Tested and Treatment Options
HSV-1 vs. HSV-2: How Herpes Spreads, How to Get Tested and Treatment Options

.. How Common Are HSV-1 and HSV-2?

 

The World Health Organization estimates that ‘‘3.8 billion
people under age 50 (64%)’’ globally have HSV-1, and ‘‘520 million people aged
15–49 (13%)’’ have HSV-2 . Most people with either virus have no symptoms or
only mild symptoms they do not recognize, and many are unaware they carry the
infection and can pass it on without knowing .

 

.. How Herpes Spreads

 

Both viruses spread through skin-to-skin contact.

 

‘‘HSV-1’’ spreads primarily through oral contact—kissing,
sharing saliva, or oral sex . The CDC notes that most people acquire oral
herpes during childhood or young adulthood from non-sexual contact with saliva.

 

‘‘HSV-2’’ spreads through sexual contact, including vaginal,
anal, and oral sex .

 

A critical point: ‘‘you can get herpes from a partner who
has no visible sores’’. Mayo Clinic states that people with herpes simplex
virus infections can pass along the virus even when they have no visible
symptoms . The virus can shed from skin that looks normal.

 

The CDC also clarifies what ‘‘does not’’ spread herpes: you
will not get it from toilet seats, bedding, swimming pools, or touching objects
like silverware, soap, or towels .

 

.. How to Get Tested

 

Because both viruses can cause sores in either location,
symptom-based identification is unreliable. The MSD Manual notes that
definitive diagnosis is best achieved through ‘‘polymerase chain reaction (PCR)
testing’’ of fluid or material swabbed from the base of a vesicle or freshly
ulcerated lesion. PCR is considered the gold standard for detecting HSV DNA,
with higher sensitivity than viral culture .

 

The MSD Manual also notes that PCR can differentiate between
HSV-1 and HSV-2, which helps guide patient care because HSV-2 has a
significantly higher recurrence rate than HSV-1 .

 

Blood tests can detect type-specific antibodies, but the CDC
notes that HSV-1 serologic testing has low sensitivity, and results cannot
determine the site of infection. A positive HSV-1 blood test tells you the
virus is present somewhere in the body, but not whether it is causing genital
symptoms.

 

.. Treatment Options: The Same Antivirals for Both

 

Treatment is identical regardless of which virus is causing
the infection. The WHO lists ‘‘acyclovir, famciclovir, and valacyclovir’’ as
the standard antiviral medicines. They can decrease how long symptoms last and
how severe they are, but they cannot cure the infection .

 

Treatment for recurrent episodes is most effective when
started ‘‘within 48 hours’’ of symptom onset .

 

For people with frequent or painful recurrences, or those
who want to lower the risk of transmitting the virus to a partner, ‘‘daily
suppressive therapy’’ is often recommended. The WHO notes that taking a lower
dose of antiviral medication every day can decrease how often symptoms occur .

 

… The 2026 Treatment Breakthrough: Pritelivir

 

On October 9, 2026, the FDA approved ‘‘pritelivir (Hovilpri)’’
for immunocompromised adults with mucocutaneous HSV lesions that have not
responded to standard therapies . This is the first antiviral with a new
mechanism of action for HSV in decades.

 

Pritelivir belongs to a new class called ‘‘helicase-primase
inhibitors’’, which block viral DNA replication directly without requiring activation
by viral thymidine kinase—the enzyme whose mutation causes resistance to
standard drugs .

 

In the Phase 3 PRIOH-1 trial of 101 immunocompromised
adults, ‘‘63% of patients on pritelivir had all lesions healed by Day 28’’,
compared with 34% on older treatments. By Day 42, 82% were healed versus 42% .
Only 2% discontinued pritelivir due to side effects, compared with 20% on
standard treatments .

 

The practical advantage is significant: pritelivir is a
once-daily oral tablet taken at home, avoiding the daily IV infusions
previously required for resistant cases .

 

‘‘Important limitation:’’ This approval is narrow. It is ‘‘not
for people with normal immune systems’’, and it does not eliminate latent
virus.

 

.. What This Means for You

 

The labels “oral” and “genital” describe
‘‘where’’ the infection is, not ‘‘which virus’’ is responsible. If you have
cold sores, you can transmit HSV-1 to a partner’s genitals through oral sex .
If you have genital herpes, it may be caused by either HSV-1 or HSV-2, and the
treatment is the same regardless.

 

If you have symptoms—blisters, ulcers, or tingling near the
mouth or genitals—see a healthcare provider for PCR testing to confirm the
diagnosis and identify the virus type . If you have no symptoms but want to
know your status, ask your provider about type-specific blood testing and its
limitations.

 

For most people with normal immune systems, standard
antivirals remain effective for managing outbreaks. For immunocompromised
patients with resistant infections, pritelivir offers a new oral option that
nearly doubled healing rates in clinical trials .

We will be happy to hear your thoughts

Leave a reply

Som2ny Network
Logo
Register New Account
Compare items
  • Total (0)
Compare
0
Shopping cart